Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma

NCT01102595 | Completed Phase 2

• 1 other identifier: GENOM-009
• Study Type: interventional
• Target: 102
• Locations: 1 country
• Sites: 1

Brief Summary

In the last 20 years, only temozolomide has obtained indication for the treatment of High-grade glioma (HGG). Temozolomide during and later radiation therapy has doubled one year survival and is the standard treatment for glioblastoma. But 30% of glioblastomas receive only a biopsy as they can't be resected and don't get benefit from this treatment. They and should be treated immediately after the biopsy to prevent neurological deterioration but in spite of this approach they often deteriorate neurologically during radiotherapy. . An effective pre-radiation treatment should improve their prognosis and allow them to complete concomitant radiotherapy and temozolomide treatment. Bevacizumab in recurrent HGG displays 63% of objective responses when combined with irinotecan. But irinotecan is not the most active treatment in this disease. We propose a phase II, two arms, open label, randomized, multicentric study with 2 cycles of temozolomide before radiation therapy and concomitant temozolomide, in patients with glioblastoma and 'biopsy-only'. Bevacizumab will be added to one arm.

Conditions

Glioblastomas

Keywords

Unresectable/inoperable glioblastomas

Outcome Measures

Primary Outcomes (1)

• Response Rate

  To determine differences in clinical activity in terms of objective response after 2 cycles of 4 weeks in both treatment arms in inoperable patients with glioblastoma (RANO criteria)

  Until the first 9 weeks of treatment

Secondary Outcomes (5)

• Percentage of patients who finish treatment

  41 weeks

• Progression-free survival

  the participants will be followed until disease progression by RANO criteria

• Number of Participants with Adverse Events as a Measure of Safety and Tolerability

  21 weeks

• Percentage of patients without neurological deterioration before radiation therapy.

  8 weeks

• Overall survival

  Until death

Study Arms (2)

1: Temozolomide plus Radiation

EXPERIMENTAL

Group 1: Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles. Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy). Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.

Drug: Temozolomide; Radiation: Standard radiation therapy

2: Temozolomide plus Radiation plus Bevacizumab

EXPERIMENTAL

Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days. Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days. Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.

Drug: Temozolomide; Drug: Bevacizumab; Radiation: Standard radiation therapy

Interventions

Temozolomide DRUG

* Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles. * Temozolomide 75 mg/m2/d x 42-49 days * Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.

1: Temozolomide plus Radiation; 2: Temozolomide plus Radiation plus Bevacizumab

Bevacizumab DRUG

* 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles. * Bevacizumab 10 mg/kg every 15 days, three dosis.

2: Temozolomide plus Radiation plus Bevacizumab

Standard radiation therapy RADIATION

42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.

1: Temozolomide plus Radiation; 2: Temozolomide plus Radiation plus Bevacizumab

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with glioblastoma, non-resectable, biopsy only. Accepting a craniotomy with resection attempted if an RMN within a period of about 72 hours to confirm that the resection was less than 25% of the tumor and fulfill criterion
• Measurable disease and contrast uptake ≥ 3 cm in one of its diameters.
• Performance Status ≤ 2.
• Age ≤ 75 years.
• MiniMental Status\> 25/30.
• Bartel index \> 50%.
• The surgical incision should be healed prior to randomization. The treatment can be started at 3 weeks of a simple stereotactic biopsy or 4 weeks in case of open biopsy (craniotomy).
• Maximum baseline MRI performed 4 weeks before starting treatment (acceptance of the MRI done for neuronavegation biopsy as baseline).
• Adequate bone marrow reserve: neutrophils\>2000x109/L, platelets\>100x109/L, hemoglobin≥106g/dl.
• Not received prior treatment with chemotherapy or radiation.
• Adequate renal function: Creatinine \<1.5 ULN of the laboratory performing the analysis.
• Adequate liver function: Serum bilirubin \<1.5/ULN SGOT, SGPT\<2.5ULN. Serum alkaline phosphatase\<3/ULN.
• Absence of proteinuria.
• Effective method of contraception for patients and their partners.
• Written informed consent

You may not qualify if:

• Prior radiotherapy or chemotherapy for the treatment of glioma.
• Less than 5 years prior to any invasive neoplasia. Accepted carcinoma in situ of cervix carcinoma or cutaneous vasocelular.
• Cerebral hemorrhage after biopsy.
• Pregnancy or lactation.
• Clinically significant cardiovascular disease: - Myocardial infarction or unstable angina (≤ 6 months before randomization) - Congestive heart failure (CHF) class ≥ II NYHA, New York Heart Association. - Cardiac Arrhythmia uncontrolled despite medication (may include patients with atrial fibrillation often controlled). - Peripheral vascular disease ≥ grade 3 (ie, symptomatic and interfering with everyday activities or specifying repairs or review).
• Continued use of aspirin\> 325 mg / day, currently or recently (within the 10 days prior to randomization).
• Currently established treatment with therapeutic doses of anticoagulants Coumarin derivatives (courmarina, warfarin) or a week before starting treatment. It allows the administration of heparin for control of Deep Vein Thrombosis (DVT)
• Patients with PTSD and patients with inflammatory bowel disease, with risk of perforation.
• HT with values above 150 mmHg systolic pressure of 100 mmHg and diastolic tension is not controllable with standard antihypertensive drugs.
• Not healed scars, ulcers or recent bone fracture.
• Bleeding diathesis or coagulopathy.

Sponsors & Collaborators

• Grupo Español de Investigación en Neurooncología: lead

Study Sites (1)

Grupo Español de Investigacion en Neurooncologia

Madrid, Madrid, 28001, Spain

Location

MeSH Terms

Conditions

Glioblastoma

Interventions

Temozolomide; Bevacizumab

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2010
• First Posted: April 13, 2010
• Study Start: December 1, 2009
• Primary Completion: October 1, 2013
• Study Completion: December 1, 2014
• Last Updated: August 26, 2015

Record last verified: 2015-08

Locations

ES (1)